Cytomedix Inc. Announces Receipt Of USPTO Allowance For Patent Covering Use Of ALDH Bright Cells In Stroke
Published: Apr 03, 2014
GAITHERSBURG, Md., April 3, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, and its wholly owned subsidiary, Aldagen, Inc., announced today the receipt of a notice of allowance for U.S. divisional patent application 12/966,401 with claims covering methods of use of ALDH bright cells in the treatment of neurological damage arising from an ischemic stroke.
Help employers find you! Check out all the jobs and post your resume.